Abstract: Objective To investigate the efficacy of foscarnet in the treatment of hematonosis plus Epstein-barr virus(EBV)infection. Methods The clinical data of 112 cases of hematonosis complicated with EBV infection treated during Jan. 2014 and Oct. 2015 were retrospectively analyzed, including 70 males and 42 females. The patients were divided into malignant group(n=84)and non-malignant group(n=18). Based on the presence of cytomegalovirus(CMV)infection and bone marrow transplantation, the malignant group was subdivided into 4 groups: simple EBV group, EBV plus CMV group, chemotherapy group, and bone marrow transplantation group. All patients were given 山 东 大 学 学 报 (医 学 版)55卷9期 -赵文博,等.膦甲酸钠治疗血液病患者合并EB病毒感染的临床疗效 \=-foscarnet 60 mg/kg per 12 hours for 14 days. Peripheral blood samples were collected weekly for blood routine test, DNA quantity of EBV and liver-kidney function analysis, to evaluate the effect and adverse reactions of the treatment. Results The total effective rate was 72.3%, which was 72.3% and 72.2% respectively for the malignant group and non-malignant group, with no statistical difference(P>0.05). There was no statistically significant difference in the effective rate between male and female groups and different age groups(P>0.05). In the malignant group, EBV plus CMV group had higher effective rate than the simple EBV group, with statistically significant difference(P<0.05), while there was no difference between the chemotherapy group and bone marrow transplantation group(P>0.05). The copies of DNA of EBV decreased after treatment. The median time for effectiveness was 10.3 to 14.5 days. Adverse reactions such as nausea and palpitation were observed, but all were tolerable. Conclusion Foscarnet is safe and effective in the treatment of EBV infection in patients with malignant hematonosis, with a few tolerable adverse reactions.

Key words: Foscarnet, Epstein-Barr virus infection, Hematonosis, Therapeutic effect